ReviewFrontiers in oncology2025
AI-based prediction of pathological risk factors in lung adenocarcinoma from CT imaging: bridging innovation and clinical practice.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bone morphogenetic protein 5 as a potential diagnostic and prognostic biomarker in lung adenocarcinoma.Translational cancer research · 2026Article
- 3D intratumoral heterogeneity-based quantitative score from chest CT for preoperative prediction of visceral pleural invasion in lung adenocarcinoma: a multicenter study.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung adenocarcinoma (LUAD) is one of the main causes of cancer-related mortality worldwide. Pathological risk factors such as spreading through air spaces, high-risk pathological subtypes, occult lymph nodes, and visceral pleural invasion have significant impact on patient prognosis. In recent years, there has been significant progress in the application of artificial intelligence (AI) technology, e.g., deep learning (DL), in medical image analysis and pathological diagnosis of lung cancer, offering novel approaches for predicting the aforementioned pathological risk factors. This article reviews recent advancements in AI-based analysis and prediction of pathological risk factors in lung adenocarcinoma, with a focus on the applications and limitations of DL models, focusing on studies aimed at improving diagnostic accuracy and efficiency for specific high-risk pathological subtypes. Finally, we summarize current challenges and future directions, emphasizing the need to expand dataset diversity and scale, improve model interpretability, and enhance the clinical applicability of AI models. This article aims to provide a reference for future research on the analysis and prediction of pathological risk factors of LUAD and to promote the development and application of AI, especially DL, in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.